Daré Bioscience Q3 2024: cash $11.2M; grants up to $10.7M and $10M; pipeline advancing

Dare Bioscience, Inc.

2024-Q3 EPS reported $0.17 revenue$73,431

Cash and equivalents $11.2M at Sept 30, 2024; R&D expenses fell 60% YoY to $2.7M; G&A $2.0M.
Foundation grant of up to ~$10.7M for novel non-hormonal contraceptive and to add Ovaprene Phase 3 sites.
ARPA-H award of $10M for DARE-HPV IND-enabling activities; NICHD grant of $2M for DARE-PTB1.
Ovaprene Phase 3 enrolling at 10 US sites; target ~125 women completing 6 mo by Q2 2025.
Sildenafil Cream Phase 3 discussions with FDA ongoing; each Phase 3 study est. ~$15M direct costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.